Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies

Clinical trial NCT02006485 · COMPLETED

Trial details

NCT number: NCT02006485
Sponsor: TG Therapeutics, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia Non-Hodgkin's Lymphoma

Start date: 2013-12-13
Primary completion: 2019-10-01
Enrollment: 160

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.